Curing the Working Capital Squeeze: Unlocking a Rating Upgrade and Permanent Cash Flow Optimization for a Global Pharma Leader

The FinMen Pharma Supply Chain Strategy In the pharmaceutical manufacturing sector, operating across multi-continental export geographies requires balancing long formulation lead times with complex international distribution networks. When capital becomes trapped in slow-moving raw materials or extended export credit periods, rating agencies quickly freeze upgrades, citing structural liquidity risks. At FinMen Advisors, we do not just manage the rating committee dialogue—we look deep into your operational supply chain. By restructuring inventory policies, implementing structured trade finance, and strategically timing the credit review around capital infusions, we turn an illiquid balance sheet into a high-velocity cash engine.

Pharmaceuticals & Drugs Industry Case Study

One Liner: Better credit rating, 30–40% improvement in free cash, leaner inventory, and permanent fund availability

Company Profile: Based out of Mumbai, pharma company was incorporated in 1987. The company manufactures pharmaceutical formulations such as tablets, syrups, capsules, and ointments. Product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral, anti-hypertensive etc. With over 35 years of experience in various pharmaceutical formulations, the company caters to customers across Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America. The company classifies its products into four groups: Generics, Pet Healthcare, Nutraceuticals and Cosmeceuticals.

Problem: Company is caught in a working capital squeeze. Inventory days are rising, meaning cash is locked up in stock that isn't moving fast enough, which restricted its rating upgrade.

Solution: We rationalised the inventory cycle — identifying the new product launches in the in various vertical, move to demand-driven procurement. Structured Debtor Management — Helped build a proper credit policy and introduce trade finance (invoice discounting, factoring) so company converts receivables to cash without sacrificing margins.

Impact: We were able to present the business cycle during the expansion, addressed the liquidity use and waited for the equity infusion announcement. Case was taken to the committee at the right time showcasing the ability and future growth drivers.

Why Pharmaceutical Manufacturers Partner with FinMen Advisors

Sustaining multi-therapeutic export operations across volatile international corridors requires a highly sophisticated liquidity framework:

• Normalizing High-Growth Inventory Spikes: We explain to rating analysts the difference between "stagnant, obsolete stock" and the strategic inventory build-up required to feed new product launches across Generics, Nutraceuticals, and Cosmeceuticals.

• Accelerating Export Receivables: We specialize in setting up and articulating cross-border trade finance mechanisms—such as factoring and invoice discounting—proving to credit committees that your international sales convert to cash rapidly without eroding product margins.

• Strategic Credit Timing: We map out your corporate milestones, ensuring your rating profile goes before the committee at the exact moment your operational improvements and equity infusions intersect for maximum rating impact.

• Monetizing Diversification Moats: We showcase your 35-year legacy, multi-format capabilities (tablets, syrups, ointments), and extensive footprint across Africa, SE Asia, and Latin America as powerful, non-cyclical mitigants against regional market shocks.

Is a temporary working capital squeeze or expanding inventory anchoring your pharma company’s credit rating? Don’t let cash locked in the supply chain limit your corporate valuation and growth prospects. Let FinMen Advisors help you optimize your cash cycles, articulate your operational efficiency, and secure the credit upgrade your global pharma footprint deserves.

Connect with FinMen Advisors today. Let’s unlock permanent liquidity for your enterprise.